Cortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society..
BACKGROUND: Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).
OBJECTIVES: The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome.
METHODS: Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data.
RESULTS: Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity.
CONCLUSIONS: Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Movement disorders : official journal of the Movement Disorder Society - 36(2021), 9 vom: 02. Sept., Seite 2104-2115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Palleis, Carla [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer's disease |
|---|
| Anmerkungen: |
Date Completed 13.10.2021 Date Revised 13.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mds.28624 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325040443 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325040443 | ||
| 003 | DE-627 | ||
| 005 | 20231225191605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mds.28624 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325040443 | ||
| 035 | |a (NLM)33951244 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Palleis, Carla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2021 | ||
| 500 | |a Date Revised 13.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. | ||
| 520 | |a BACKGROUND: Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases) | ||
| 520 | |a OBJECTIVES: The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome | ||
| 520 | |a METHODS: Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data | ||
| 520 | |a RESULTS: Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity | ||
| 520 | |a CONCLUSIONS: Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a corticobasal syndrome | |
| 650 | 4 | |a four-repeat tauopathies | |
| 650 | 4 | |a tau | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 700 | 1 | |a Brendel, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Finze, Anika |e verfasserin |4 aut | |
| 700 | 1 | |a Weidinger, Endy |e verfasserin |4 aut | |
| 700 | 1 | |a Bötzel, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Danek, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Beyer, Leonie |e verfasserin |4 aut | |
| 700 | 1 | |a Nitschmann, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Biechele, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Rauchmann, Boris-Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Häckert, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Höllerhage, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, Andrew W |e verfasserin |4 aut | |
| 700 | 1 | |a Drzezga, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a van Eimeren, Thilo |e verfasserin |4 aut | |
| 700 | 1 | |a Villemagne, Victor L |e verfasserin |4 aut | |
| 700 | 1 | |a Schildan, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Barthel, Henryk |e verfasserin |4 aut | |
| 700 | 1 | |a Patt, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Sabri, Osama |e verfasserin |4 aut | |
| 700 | 0 | |a German Imaging Initiative for Tauopathies (GII4T) |e verfasserin |4 aut | |
| 700 | 1 | |a Bartenstein, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Perneczky, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Haass, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Höglinger, Günter U |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Movement disorders : official journal of the Movement Disorder Society |d 1995 |g 36(2021), 9 vom: 02. Sept., Seite 2104-2115 |w (DE-627)NLM012945846 |x 1531-8257 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:9 |g day:02 |g month:09 |g pages:2104-2115 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mds.28624 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 9 |b 02 |c 09 |h 2104-2115 | ||